Royalty Pharma PLC (RPRX)

Royalty Pharma (RPRX) Financial Statements


Royalty Pharma Financial Overview

Royalty Pharma's market cap is currently ―. The company's EPS TTM is $0.112; its P/E ratio is 313.82; and it has a dividend yield of 2.17%. Royalty Pharma is scheduled to report earnings on May 4, 2023, and the estimated EPS forecast is $0.83. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue$ 565.75M$ 573.46M$ 535.96M$ 562.05M$ 575.70M
Gross Profit-----
EBIT$ -563.08M$ 267.39M$ 538.56M$ 175.15M$ 100.64M
EBITDA$ -563.08M$ 267.39M$ 538.56M$ 180.82M$ 106.44M
Net Income Common Stockholders$ -456.08M$ 142.65M$ 304.50M$ 51.76M$ 7.90M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.43B$ 2.22B$ 3.40B$ 2.91B$ 2.80B
Total Assets$ 16.81B$ 17.67B$ 17.74B$ 17.38B$ 17.52B
Total Debt$ 7.12B$ 7.11B$ 7.11B$ 7.10B$ 7.10B
Net Debt$ 4.69B$ 4.89B$ 3.70B$ 4.19B$ 4.29B
Total Liabilities$ 7.29B$ 7.26B$ 7.33B$ 7.24B$ 7.27B
Stockholders Equity$ 5.63B$ 6.15B$ 6.03B$ 5.78B$ 5.78B
Cash Flow-
Free Cash Flow$ 569.93M$ 538.83M$ 574.95M$ 460.27M$ 489.96M
Operating Cash Flow$ 569.93M$ 538.83M$ 574.95M$ 460.27M$ 489.96M
Investing Cash Flow$ 414.74M$ -1.43B$ -30.18M$ 11.16M$ -551.65M
Financing Cash Flow$ -265.55M$ -230.09M$ -228.25M$ -220.97M$ -198.07M
Currency in USD

Royalty Pharma Earnings and Revenue History

Royalty Pharma Debt to Assets

Royalty Pharma Cash Flow

Royalty Pharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis